je.st
news
Tag: amgen
Amgen reports positive preliminary results on leukemia drug
2015-07-17 19:38:55| Biotech - Topix.net
Amgen Inc on Thursday said some patients with a deadly form of leukemia experienced complete remission after being treated with its Blincyto drug in a midstage clinical trial, results that could eventually lead to an expanded approval of the pricy cancer medicine. While providing few details, the world's largest biotechnology company said the drug, which helps the immune system to fight cancer, induced complete remission or complete remission with partial hematological recovery in a "clinically meaningful number of patients" with relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia .
Tags: results
reports
positive
drug
Biotech Short-Sellers Prefer Amgen To Gilead Sciences
2015-06-28 01:32:55| Biotech - Topix.net
Some of the biggest swings in short interest among the leading biotechs and emerging pharmaceuticals between the May 29 and June 15 settlement dates happened to Amgen, Inc. , Gilead Sciences, Inc. and Illumina, Inc. . Let's take a quick look at how these three stocks have fared recently and what analysts expect from them.
Tags: sciences
prefer
biotech
gilead
FDA panel backs Amgen cholesterol drug for some patients
2015-06-11 08:41:53| Biotech - Topix.net
" Federal health advisers said that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance. But as with their review of a similar drug a day earlier, the Food and Drug Administration experts stressed Wednesday that long-term results are needed to judge the drug's real benefit.
Tags: panel
drug
patients
backs
Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer
2015-05-29 14:30:32| Merck.com - Product News
Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Companies Also Plan to Initiate Phase 3 Trial in Combination for Advanced Melanoma THOUSAND OAKS, Calif. and KENILWORTH, N.J., - May 29, 2015 Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgens investigational oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Language: English read more
Tags: with
support
head
studies
Amgen ends partnership with AstraZeneca on inflammation drug
2015-05-23 01:30:34| Biotech - Topix.net
Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.
Tags: drug
partnership
ends
inflammation
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] next »